DAFTAR PUSTAKA

Avila-Nava, A., Cortes-Telles, A., Torres-Erazo, D., López-Romero, S., Chim Aké, R., & Gutiérrez Solis, A. L. (2021). Serum IL-6: A potential biomarker of mortality among SARS-CoV-2 infected patients in Mexico. *Cytokine*, *143*, 155543. https://doi.org/10.1016/J.CYTO.2021.155543

Buicu, A. L., Cernea, S., Benedek, I., Buicu, C. F., & Benedek, T. (2021). Systemic Inflammation and COVID-19 Mortality in Patients with Major Noncommunicable Diseases: Chronic Coronary Syndromes, Diabetes and Obesity. *Journal of Clinical Medicine 2021, Vol. 10, Page 1545*, *10*(8), 1545. https://doi.org/10.3390/JCM10081545

Bwire, G. M. (2020). Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? *SN Comprehensive Clinical Medicine 2020 2:7*, *2*(7), 874–876. https://doi.org/10.1007/S42399-020-00341-W

Chen, C., Li, H., Hang, W., & Wang, D. W. (2020). Cardiac injuries in coronavirus disease 2019 (COVID-19). *Journal of Molecular and Cellular Cardiology*, *145*, 25–29. https://doi.org/10.1016/J.YJMCC.2020.06.002

Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., Wang, T., Guo, W., Chen, J., Ding, C., Zhang, X., Huang, J., Han, M., Li, S., Luo, X., … Ning, Q. (2020). Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*, *368*. https://doi.org/10.1136/BMJ.M1091

Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C., & Melguizo-Rodríguez, L. (2020). SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. *Cytokine & Growth Factor Reviews*, *54*, 62–75. https://doi.org/10.1016/J.CYTOGFR.2020.06.001

Echarte-Morales, J., Minguito-Carazo, C., Cepas-Guillén, P. L., Vallejo García, V., Poveda Pinedo, I. D., Martínez Gómez, E., Sánchez Muñoz, E., López Benito, M., Salazar Rodríguez, A., Cruz-González, I., Arbas Redondo, E., Benito-González, T., Guzmán-Bofarull, J., Tebar Márquez, D., Viana Tejedor, A., Sánchez Fernández, P. L., Sabaté, and, M., & Fernández-Vázquez, F. (2022). Incidence, morbidity and mortality, and management of acute coronary syndrome during the time of COVID-19 lockdown. *REC: Interventional Cardiology (English Edition)*. https://doi.org/10.24875/RECICE.M22000270

Fanola, C. L., Morrow, D. A., Cannon, C. P., Jarolim, P., Lukas, M. A., Bode, C., Hochman, J. S., Goodrich, E. L., Braunwald, E., & O'Donoghue, M. L. (2017). Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: Observations from the SOLID-TIMI 52 (stabilization of plaque using darapladib-thrombolysis in myocardial infarction 52) trial. *Journal of the American Heart Association*, *6*(10). https://doi.org/10.1161/JAHA.117.005637

Fu, B., Xu, X., & Wei, H. (2020). Why tocilizumab could be an effective treatment for severe COVID-19? *Journal of Translational Medicine*, *18*(1). https://doi.org/10.1186/S12967-020-02339-3

Gagliardi, M. C., Tieri, P., Ortona, E., & Ruggieri, A. (2020). ACE2 expression and sex disparity in COVID-19. *Cell Death Discovery 2020 6:1*, *6*(1), 1–2. https://doi.org/10.1038/s41420-020-0276-1

Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.

E., Katsaounou, P., Ntaganou, M., Kyriakopoulou, M., Dimopoulos, G., Koutsodimitropoulos, I., Velissaris, D., Koufargyris, P., Karageorgos, A., Katrini, K., Lekakis, V., … Koutsoukou, A. (2020). Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. *Cell Host & Microbe*, *27*(6), 992-1000.e3. https://doi.org/10.1016/J.CHOM.2020.04.009

Gordon, J. S., & Drazner, M. H. (2021). Biomarkers of Cardiac Stress and Cytokine Release Syndrome in COVID-19: A Review. *Current Heart Failure Reports*, *18*(3), 163–168. https://doi.org/10.1007/S11897-021-00505-2

Inciardi, R. M., Adamo, M., Lupi, L., Cani, D. S., Di Pasquale, M., Tomasoni, D., Italia, L., Zaccone, G., Tedino, C., Fabbricatore, D., Curnis, A., Faggiano, P., Gorga, E., Lombardi, C. M., Milesi, G., Vizzardi, E., Volpini, M., Nodari, S., Specchia, C., … Metra, M. (2020). Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. *European Heart Journal*, *41*(19), 1821–1829. https://doi.org/10.1093/EURHEARTJ/EHAA388

Inciardi, R. M., Lupi, L., Zaccone, G., Italia, L., Raffo, M., Tomasoni, D., Cani, D. S., Cerini, M., Farina, D., Gavazzi, E., Maroldi, R., Adamo, M., Ammirati, E., Sinagra, G., Lombardi, C. M., & Metra, M. (2020). Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology*, *5*(7), 819–824. https://doi.org/10.1001/JAMACARDIO.2020.1096

Lazou, A., Ikonomidis, I., Bartekova, M., Benedek, T., Makavos, G., Palioura, D., Cabrera Fuentes, H., & Andreadou, I. (2020). Chronic inflammatory diseases, myocardial function and cardioprotection. *British Journal of Pharmacology*, *177*(23), 5357–5374. https://doi.org/10.1111/BPH.14975

Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T., Kucher, N., Studt, J. D., Sacco, C., Alexia, B., Sandri, M. T., & Barco, S. (2020). Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thrombosis Research*, *191*, 9–14. https://doi.org/10.1016/j.thromres.2020.04.024

Middeldorp, S., Coppens, M., van Haaps, T. F., Foppen, M., Vlaar, A. P., Müller, M. C. A., Bouman, C. C. S., Beenen, L. F. M., Kootte, R. S., Heijmans, J., Smits, L. P., Bonta, P. I., & van Es, N. (2020). Incidence of venous thromboembolism in hospitalized patients with COVID-19. *Journal of Thrombosis and Haemostasis*, *18*(8), 1995–2002. https://doi.org/10.1111/JTH.14888

Netea, M. G., Balkwill, F., Chonchol, M., Cominelli, F., Donath, M. Y., Giamarellos-Bourboulis, E. J., Golenbock, D., Gresnigt, M. S., Heneka, M. T., Hoffman, H. M., Hotchkiss, R., Joosten, L. A. B., Kastner, D. L., Korte, M., Latz, E., Libby, P., Mandrup-Poulsen, T., Mantovani, A., Mills, K. H. G., … Dinarello, C. A. (2017). A guiding map for inflammation. *Nature Immunology*, *18*(8), 826–831. https://doi.org/10.1038/NI.3790

Phan, F., Boussouar, S., Lucidarme, O., Zarai, M., Salem, J. E., Kachenoura, N., Bouazizi, K., Charpentier, E., Niati, Y., Bekkaoui, H., Amoura, Z., Mathian, A., Benveniste, O., Cacoub, P., Allenbach, Y., Saadoun, D., Lacorte, J. M., Fourati, S., Laroche, S., … Redheuil, A. (2021). Cardiac adipose tissue volume and IL-6 level at admission are complementary predictors of severity and short-term mortality in COVID-19 diabetic

patients. *Cardiovascular Diabetology*, *20*(1), 1–10. https://doi.org/10.1186/S12933-021-01327-1/FIGURES/4

Rahayu, R., Winarto, W., & Nasihun, T. (2022). Interleukin-6 and C-reactive Protein on Admission as Predictor of Mortality in Severe COVID-19 Patients: A Retrospective Cohort Study. *Open Access Macedonian Journal of Medical Sciences*, *10*(B), 227–231. https://doi.org/10.3889/oamjms.2022.7968

Rashid, M., Wu, J., Timmis, A., Curzen, N., Clarke, S., Zaman, A., Nolan, J., Shoaib, A., Mohamed, M. O., de Belder, M. A., Deanfield, J., Gale, C. P., & Mamas, M. A. (2021). Outcomes of COVID-19-positive acute coronary syndrome patients: A multisource electronic healthcare records study from England. *Journal of Internal Medicine*, *290*(1), 88–100. https://doi.org/10.1111/JOIM.13246

Rattka, M., Dreyhaupt, J., Winsauer, C., Stuhler, L., Baumhardt, M., Thiessen, K., Rottbauer, W., & Imhof, A. (2020). Effect of the COVID-19 pandemic on mortality of patients with STEMI: a systematic review and meta-analysis. *Heart (British Cardiac Society)*, *107*(6), 482–487. https://doi.org/10.1136/HEARTJNL-2020-318360

Ridker, P. M. (2016). From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. *Circulation Research*, *118*(1), 145–156. https://doi.org/10.1161/CIRCRESAHA.115.306656

Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., Kastelein, J. J. P., Cornel, J. H., Pais, P., Pella, D., Genest, J., Cifkova, R., Lorenzatti, A., Forster, T., Kobalava, Z., … Glynn, R. J. (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *The New England Journal of Medicine*, *377*(12), 1119–1131. https://doi.org/10.1056/NEJMOA1707914

Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Medicine*, *46*(5), 846–848. https://doi.org/10.1007/S00134-020-05991-X

Saad, M., Kennedy, K. F., Imran, H., Louis, D. W., Shippey, E., Poppas, A., Wood, K. E., Abbott, J. D., & Aronow, H. D. (2021). Association Between COVID-19 Diagnosis and In-Hospital Mortality in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction. *JAMA*, *326*(19), 1940–1952. https://doi.org/10.1001/JAMA.2021.18890

Sadeq, A., Al Saffar, H., & Alabdali, S. (2022). Inflammatory markers in patients who presented with acute coronary syndrome and history of COVID-19 infection: a cross-sectional study. *F1000Research 2022 11:987*, *11*, 987. https://doi.org/10.12688/f1000research.123896.1

Salinas, P., Travieso, A., Vergara-Uzcategui, C., Tirado-Conte, G., Macaya, F., Mejía-Rentería, H., Nombela-Franco, L., Núñez-Gil, I. J., Gonzalo, N., Jiménez-Quevedo, P., Pérez-Vizcayno, M. J., Escaned, J., & Fernández-Ortiz, A. (2021). Clinical Profile and 30-Day Mortality of Invasively Managed Patients with Suspected Acute Coronary Syndrome During the COVID-19 Outbreak. *International Heart Journal*, *62*(2), 274–281. https://doi.org/10.1536/IHJ.20-574

Santoso, A., Pranata, R., Wibowo, A., Al-Farabi, M. J., Huang, I., & Antariksa,

B. (2021). Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis. *The American Journal of Emergency Medicine*, *44*, 352–357. https://doi.org/10.1016/J.AJEM.2020.04.052

Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., Gong, W., Liu, X., Liang, J., Zhao, Q., Huang, H., Yang, B., & Huang, C. (2020). Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiology*, *5*(7), 802–810. https://doi.org/10.1001/JAMACARDIO.2020.0950

Sukorini, T. T. J. P. U. (2015). Correlation of interleukin-6 and monocyte count to troponin I in acute coronary syndrome. *Journal of the Medical Sciences (Berkala Ilmu Kedokteran)*, *40*(04).

Tøllefsen, I. M., Shetelig, C., Seljeflot, I., Eritsland, J., Hoffmann, P., & Andersen, G. Ø. (2021). High levels of interleukin-6 are associated with final infarct size and adverse clinical events in patients with STEMI. *Open Heart*, *8*(2). https://doi.org/10.1136/OPENHRT-2021-001869

Wichmann, D., Sperhake, J. P., Lütgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F., Mushumba, H., Kniep, I., Schröder, A. S., Burdelski, C., de Heer, G., Nierhaus, A., Frings, D., Pfefferle, S., Becker, H., Bredereke-Wiedling, H., de Weerth, A., Paschen, H. R., … Kluge, S. (2020). Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. *Annals of Internal Medicine*, *173*(4), 268–277. https://doi.org/10.7326/M20-2003

Zamani, P., Schwartz, G. G., Olsson, A. G., Rifai, N., Bao, W., Libby, P., Ganz, P., Kinlay, S., & Myocardial Ischemia Reduction with Aggressive Cholesterol. (2013). Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. *Journal of the American Heart Association*, *2*(1). https://doi.org/10.1161/JAHA.112.003103

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)*, *395*(10229), 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3

Zhou, J., He, W., Liang, J., Wang, L., Yu, X., Bao, M., & Liu, H. (2021). Association of Interleukin-6 Levels with Morbidity and Mortality in Patients with Coronavirus Disease 2019 (COVID-19). *Japanese Journal of Infectious Diseases*, *74*(4), 293–298. https://doi.org/10.7883/YOKEN.JJID.2020.463

Lampiran


ROC Curve
Sensitivity
1 – Specificity
0.0
0.2
0.4
0.6
0.8
1.0
Source of the Curve
Reference Line
troponin

Lampiran Rekomendasi Persetujuan Etik Fakultas Kedokteran, Universitas Hasanuddin

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari,.MMed,PhD, SpGK. TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 727/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 15 Nopember 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22090562	No Sponsor Protokol	
Peneliti Utama	**dr. Khairani Ummah, S.Ked**	Sponsor	
Judul Peneliti	Nilai serum Interliukin 6 pada pasien Covid 19 dengan Komorbid Kardiovaskular		
No Versi Protokol	**2**	Tanggal Versi	**13 Nopember 2022**
No Versi PSP	**2**	Tanggal Versi	**13 Nopember 2022**
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **15 Nopember 2022** sampai **15 Nopember 2023**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan